Buprenorphine

Major

Buprenorphine Acetaminophen And Codeine Capital® & Codeine Explained Reduced analgesic effect and/or precipitation of withdrawal symptoms, an increased risk of serotonin syndrome and an increased ris... Details Buprenorphine Acecainide Explained Increased risk of QT prolongation Details Buprenorphine Acepromazine PROMACE Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Aclidinium Tudorza Explained An increased risk of paralytic ileus Details Buprenorphine Adagrasib Krazati Explained An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Buprenorphine Alfentanil Explained An increased risk of CNS depression, profound sedation, respiratory depression, hypotension, coma and death, reduced analgesic eff... Details Buprenorphine Alfuzosin UroXatral An increased risk of QT interval prolongation Details Buprenorphine Almotriptan Explained An increased risk of serotonin syndrome Details Buprenorphine Alprazolam Xanax Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Amantadine Explained An increased risk of paralytic ileus Details Buprenorphine Amiloride Explained Reduced efficacy of diuretics Details Buprenorphine Amineptine Explained An increased risk of serotonin syndrome Details Buprenorphine Amiodarone Nexterone Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Amisulpride Barhemsys Explained Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Buprenorphine Amitriptyline Elavil Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Amitriptylinoxide Explained An increased risk of serotonin syndrome Details Buprenorphine Amobarbital Amytal Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Amoxapine Explained An increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Amphetamine Dexedrine Explained An increased risk of serotonin syndrome Details Buprenorphine Amprenavir Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Anagrelide Agrylin An increased risk of QT interval prolongation Details Buprenorphine Anileridine Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Apalutamide Erleada Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Apomorphine Apokyn Explained An increased risk of QT interval prolongation Details Buprenorphine Aprepitant Aponvie Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Aripiprazole Abilify Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Aripiprazole Lauroxil Aristada Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Armodafinil Nuvigil Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Arsenic Trioxide Trisenox Explained An increased risk of QT interval prolongation Details Buprenorphine Artemether Explained An increased risk of QT interval prolongation, reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Buprenorphine Asenapine Saphris Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Astemizole Explained An increased risk of QT interval prolongation Details Buprenorphine Atazanavir Reyataz Explained An increased risk of QT interval prolongation, increased buprenorphine exposure, an increased risk of buprenorphine-related advers... Details Buprenorphine Atropine Atropen Explained An increased risk of paralytic ileus Details Buprenorphine Avacopan Tavneos Explained Increased CYP3A4 substrate exposure Details Buprenorphine Azithromycin AzaSite Explained An increased risk of QT interval prolongation Details Buprenorphine Baclofen Fleqsuvy Explained Enhanced neuromuscular blocking action and an increased risk of respiratory depression and CNS depression Details Buprenorphine Bedaquiline Sirturo An increased risk of QT interval prolongation Details Buprenorphine Belladonna Explained An increased risk of paralytic ileus Details Buprenorphine Bemetizide Explained Reduced efficacy of diuretics Details